Preventing chronic graft-versus-host disease (GVHD) remains challenging because the
unique cellular and molecular pathways that incite chronic GVHD are poorly understood …

Regenerative failure at barrier surfaces and maladaptive repair leading to fibrosis are
hallmarks of graft-versus-host disease (GVHD). Although immunosuppressive treatment can …

Castleman disease (CD) is a rare lymphoproliferative disorder. Among subtypes of CD,
idiopathic multicentric CD-not otherwise specified (iMCD-NOS) has a poor prognosis and its …

As a result of impressive increases in our knowledge of rodent and human immunology, the
understanding of the pathophysiologic mechanisms underlying graft-versus-host disease …

Severe acute and chronic graft versus host disease (GVHD) remains a major cause of
morbidity and mortality after allogeneic hematopoietic cell transplantation. Historically, cord …

Chronic Graft-versus-Host Disease is a life-threatening inflammatory condition that affects
many patients after allogeneic hematopoietic stem cell transplantation. Although we have …

Chronic graft‐versus‐host disease (cGVHD) is a major complication affecting the long‐term
survival of patients after allogeneic haematopoietic stem cell transplantation. The …

Posttransplant cyclophosphamide (PTCy) is associated with a low incidence of chronic graft-
versus-host disease (cGVHD) following hematopoietic stem cell (HSC) transplantation …

Chronic graft-versus-host disease (cGVHD) is one of the most common reasons of late non-
relapse morbidity and mortality of patients with allogeneic hematopoietic stem cell …

Recent studies indicated that regulatory B cells (Bregs) and nuclear factor erythroid 2-
related factor 2 (Nrf2) antioxidant signaling pathway play important roles in the pathogenesis …